Maxcyte, Inc. MXCT
We take great care to ensure that the data presented and summarized in this overview for MAXCYTE, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MXCT
View all-
Black Rock Inc. New York, NY7.23MShares$35.8 Million0.0% of portfolio
-
Cadian Capital Management, LP New York, NY6.56MShares$32.5 Million0.98% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny6.17MShares$30.5 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.35MShares$26.5 Million0.0% of portfolio
-
Vitruvian Partners LLP5.04MShares$25 Million6.7% of portfolio
-
Morgan Stanley New York, NY3.52MShares$17.4 Million0.0% of portfolio
-
Massachusetts Financial Services CO Boston, MA2.53MShares$12.5 Million0.0% of portfolio
-
Mudita Advisors LLP London, X02.28MShares$11.3 Million5.68% of portfolio
-
Geode Capital Management, LLC Boston, MA2.13MShares$10.5 Million0.0% of portfolio
-
State Street Corp Boston, MA1.99MShares$9.83 Million0.0% of portfolio
Latest Institutional Activity in MXCT
Top Purchases
Top Sells
About MXCT
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
Insider Transactions at MXCT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 20
2024
|
Thomas M. Ross EVP, GLOBAL SALES |
SELL
Open market or private sale
|
Direct |
33,333
-57.14%
|
$133,332
$4.09 P/Share
|
|
Jun 20
2024
|
Thomas M. Ross EVP, GLOBAL SALES |
BUY
Exercise of conversion of derivative security
|
Direct |
33,333
+36.36%
|
$33,333
$1.64 P/Share
|
|
Jun 11
2024
|
Richard Douglas |
BUY
Grant, award, or other acquisition
|
Direct |
21,367
+14.97%
|
-
|
|
Jun 11
2024
|
Art Mandell |
BUY
Grant, award, or other acquisition
|
Direct |
21,367
+5.12%
|
-
|
|
Jun 11
2024
|
Stanley C Erck |
BUY
Grant, award, or other acquisition
|
Direct |
21,367
+7.36%
|
-
|
|
Jun 11
2024
|
Rekha Hemrajani |
BUY
Grant, award, or other acquisition
|
Direct |
21,367
+50.0%
|
-
|
|
Jun 11
2024
|
Patrick J Balthrop |
BUY
Grant, award, or other acquisition
|
Direct |
21,367
+50.0%
|
-
|
|
Jun 11
2024
|
John Joseph Johnston |
BUY
Grant, award, or other acquisition
|
Direct |
21,367
+13.08%
|
-
|
|
Jun 11
2024
|
Yasir B. Al Wakeel |
BUY
Grant, award, or other acquisition
|
Direct |
21,367
+50.0%
|
-
|
|
Jun 11
2024
|
William W Brooke |
BUY
Grant, award, or other acquisition
|
Direct |
21,367
+22.97%
|
-
|
|
Jun 10
2024
|
Maher Masoud President and CEO |
BUY
Open market or private purchase
|
Direct |
70,443
+41.33%
|
$281,772
$4.9 P/Share
|
|
Jun 07
2024
|
Maher Masoud President and CEO |
BUY
Open market or private purchase
|
Direct |
29,557
+50.0%
|
$118,228
$4.87 P/Share
|
|
Mar 26
2024
|
John Joseph Johnston |
SELL
Open market or private sale
|
Direct |
5,000
-3.98%
|
$20,000
$4.41 P/Share
|
|
Mar 26
2024
|
John Joseph Johnston |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+3.83%
|
$10,000
$2.14 P/Share
|
|
Mar 15
2024
|
David I. Sandoval GENERAL COUNSEL |
BUY
Grant, award, or other acquisition
|
Direct |
3,913
+7.85%
|
-
|
|
Mar 15
2024
|
Thomas M. Ross EVP, GLOBAL SALES |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+50.0%
|
-
|
|
Mar 15
2024
|
Douglas J Swirsky CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
81,250
+50.0%
|
-
|
|
Feb 26
2024
|
John Joseph Johnston |
SELL
Open market or private sale
|
Direct |
5,000
-3.98%
|
$20,000
$4.6 P/Share
|
|
Feb 26
2024
|
John Joseph Johnston |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+3.83%
|
$10,000
$2.14 P/Share
|
|
Jan 26
2024
|
John Joseph Johnston |
SELL
Open market or private sale
|
Direct |
5,000
-3.98%
|
$25,000
$5.12 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 281K shares |
|---|---|
| Exercise of conversion of derivative security | 273K shares |
| Open market or private purchase | 100K shares |
| Open market or private sale | 273K shares |
|---|